Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo/Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Pain Treatment

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo/Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Pain Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anrikefon (Primary) ; Tramadol (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Haisco Pharmaceutical Group

Most Recent Events

  • 12 May 2026 According to a Zhejiang Hisun Pharmaceutical media release, the National Medical Products Administration recently issued an acceptance Notice formally notifying the acceptance of Hisun Pharmaceutical's Anrikefon application for marketing authorization for the treatment of postoperative pain.
  • 03 Apr 2023 Status changed from recruiting to completed.
  • 09 Feb 2023 Planned number of patients changed from 285 to 387.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top